Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib plus re-induction chemotherapy in pediatric and young adult relapsed/refractory FLT3-ITD AML
2023-510009-16-00Phase 2Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Composite complete remission rate after up to 2 re-induction cycles, Safety profile and 2 more. Planned start Apr 2024; status: authorised.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-510009-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510009-16-00.